ReviewNature reviews. Nephrology2016
The importance of non-HLA antibodies in transplantation.
Review in Nature reviews. Nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it, 205 citations in OpenAlex.
- Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment.Frontiers in immunology · 2024Pooled it
- Non-HLA Antibodies and Epitope Mismatches in Kidney Transplant Recipients With Histological Antibody-Mediated Rejection.Frontiers in immunology · 2021Trial
- Pre-transplant evaluation of immunological risk in paediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2026Review
- Apparentness of Unseen Rejection Episodes Post Lung rLTx Is Reliably Enabled by ddcfDNA Detection.HLA · 2026Article
- Antibodies to Non-HLA Antigens and Their Role in Organ Transplant Rejection.International journal of immunogenetics · 2026Review
- Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?Medical sciences (Basel, Switzerland) · 2026Review
- Advances in HLA and Non-HLA Immune Profiling: Integrating Next-Generation Sequencing and Artificial Intelligence in Transplantation.Annals of laboratory medicine · 2026Review
- Autoreactive antibody production by intrarenal B cells in mouse kidney allograft rejection.bioRxiv : the preprint server for biology · 2026Article
- The natural killer-cellular humoral activation test as a functional biomarker of antibody-mediated rejection after kidney transplantation.Scientific reports · 2026Article
- Dual inhibition of mTOR and calcineurin pathways mitigates missing self-induced NK cell-mediated microvascular rejection.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Treatment of antibody-mediated rejection in heart transplantation: from empirical combination to multi-target precision intervention.Frontiers in immunology · 2026Review
- XBP1s-Orchestrated Soluble Mediators: Participants of Oxidative Stress in Renal Ischemia-Reperfusion Injury Following Donation After Circulatory Death.Mediators of inflammation · 2026Review
- The risk of kidney transplant graft loss in sensitized vs. unsensitized patients is modified by prior transplant status.Frontiers in transplantation · 2026Article
- Understanding the role of non-HLA antibodies in kidney transplantation: a literature review.Frontiers in immunology · 2026Review
- Non-HLA antibody trajectories may predict kidney transplant outcomes.Frontiers in immunology · 2026Article
- Antibodies to angiotensin II type 1 receptor and endothelin type A receptor are associated with cytokine production enriched for type 2 immune response and antibody production in pediatric kidney transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025Article
- Non-human leukocyte antigen antibodies in kidney transplantation: pathogenic mechanisms, detection methods, and clinical implications.Clinical transplantation and research · 2025Review
- Inhibition of De Novo Autoantibody Production Attenuates Chronic Antibody-Mediated Rejection of Kidney Allografts Despite Maintenance of High Donor-Specific Antibody Titers.bioRxiv : the preprint server for biology · 2025Article
- [Immunological Aspects after Lung Transplantation].Zentralblatt fur Chirurgie · 2025Review
- Development of the Crossmatch Test in Kidney Transplantation Up to the Virtual Level.Journal of clinical medicine · 2025Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The development of post-transplantation antibodies against non-HLA autoantigens is associated with rejection and decreased long-term graft survival. Although our knowledge of non-HLA antibodies is incomplete, compelling experimental and clinical findings demonstrate that antibodies directed against autoantigens such as angiotensin type 1 receptor, perlecan and collagen, contribute to the process of antibody-mediated acute and chronic rejection. The mechanisms that underlie the production of autoantibodies in the setting of organ transplantation is an important area of ongoing investigation. Ischaemia-reperfusion injury, surgical trauma and/or alloimmune responses can result in the release of organ-derived autoantigens (such as soluble antigens, extracellular vesicles or apoptotic bodies) that are presented to B cells in the context of the transplant recipient's antigen presenting cells and stimulate autoantibody production. Type 17 T helper cells orchestrate autoantibody production by supporting the proliferation and maturation of autoreactive B cells within ectopic tertiary lymphoid tissue. Conversely, autoantibody-mediated graft damage can trigger alloimmunity and the development of donor-specific HLA antibodies that can act in synergy to promote allograft rejection. Identification of the immunologic phenotypes of transplant recipients at risk of non-HLA antibody-mediated rejection, and the development of targeted therapies to treat such rejection, are sorely needed to improve both graft and patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.